دورية أكاديمية

Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms

التفاصيل البيبلوغرافية
العنوان: Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms
المؤلفون: M. Abdel-fattah, C. Chapple, K. Guerrero, S. Dixon, N. Cotterill, K. Ward, H. Hashim, A. Monga, K. Brown, M. J. Drake, A. Gammie, A. Mostafa, U. K. Bladder Health, S. Breeman, D. Cooper, G. MacLennan, J. Norrie
المصدر: Trials, Vol 22, Iss 1, Pp 1-18 (2021)
بيانات النشر: BMC, 2021.
سنة النشر: 2021
المجموعة: LCC:Medicine (General)
مصطلحات موضوعية: Female, Urodynamics, Overactive bladder, Randomised controlled trial, Uroflowmetry, Filling cystometry, Medicine (General), R5-920
الوصف: Abstract Background Overactive bladder (OAB) syndrome is a symptom complex affecting 12–14% of the UK adult female population. Symptoms include urinary urgency, with or without urgency incontinence, increased daytime urinary frequency and nocturia. OAB has a negative impact on women’s social, physical, and psychological wellbeing. Initial treatment includes lifestyle modifications, bladder retraining, pelvic floor exercises and pharmacological therapy. However, these measures are unsuccessful in 25–40% of women (refractory OAB). Before considering invasive treatments, such as Botulinum toxin injection or sacral neuromodulation, most guidelines recommend urodynamics to confirm diagnosis of detrusor overactivity (DO). However, urodynamics may fail to show evidence of DO in up to 45% of cases, hence the need to evaluate its effectiveness and cost-effectiveness. FUTURE (Female Urgency, Trial of Urodynamics as Routine Evaluation) aims to test the hypothesis that, in women with refractory OAB, urodynamics and comprehensive clinical assessment is associated with superior patient-reported outcomes following treatment and is more cost-effective, compared to comprehensive clinical assessment only. Methods FUTURE is a pragmatic, multi-centre, superiority randomised controlled trial. Women aged ≥ 18 years with refractory OAB or urgency predominant mixed urinary incontinence, and who have failed/not tolerated conservative and medical treatment, are considered for trial entry. We aim to recruit 1096 women from approximately 60 secondary/tertiary care hospitals across the UK. All consenting women will complete questionnaires at baseline, 3 months, 6 months and 15 months post-randomisation. The primary outcome is participant-reported success at 15 months post-randomisation measured using the Patient Global Impression of Improvement. The primary economic outcome is incremental cost per quality-adjusted life year gained at 15 months. The secondary outcomes include adverse events, impact on other urinary symptoms and health-related quality of life. Qualitative interviews with participants and clinicians and a health economic evaluation will also be conducted. The statistical analysis of the primary outcome will be by intention-to-treat. Results will be presented as estimates and 95% CIs. Discussion The FUTURE study will inform patients, clinicians and policy makers whether routine urodynamics improves treatment outcomes in women with refractory OAB and whether it is cost-effective. Trial registration ISRCTN63268739 . Registered on 14 September 2017.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1745-6215
Relation: https://doaj.org/toc/1745-6215
DOI: 10.1186/s13063-021-05661-3
URL الوصول: https://doaj.org/article/cb9d943bf047458882de3f22afa3625c
رقم الأكسشن: edsdoj.b9d943bf047458882de3f22afa3625c
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:17456215
DOI:10.1186/s13063-021-05661-3